These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 32301699

  • 1. Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
    Song GG, Lee YH.
    Int J Clin Pharmacol Ther; 2020 Jun; 58(6):293-298. PubMed ID: 32301699
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Song GG.
    Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Song GG, Lee YH.
    Z Rheumatol; 2020 Feb; 79(1):103-111. PubMed ID: 30725185
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC, Song GG.
    Rheumatol Int; 2015 Dec; 35(12):1965-74. PubMed ID: 25994093
    [Abstract] [Full Text] [Related]

  • 5. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
    Lee YH, Song GG.
    Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
    [Abstract] [Full Text] [Related]

  • 6. Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Z Rheumatol; 2018 May; 77(4):335-342. PubMed ID: 28097393
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
    Bae SC, Lee YH.
    Z Rheumatol; 2018 Jun; 77(5):421-428. PubMed ID: 28324148
    [Abstract] [Full Text] [Related]

  • 8. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
    Bae SC, Lee YH.
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Bae SC, Lee YH.
    Int J Rheum Dis; 2018 May; 21(5):922-929. PubMed ID: 29671942
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG, Choi SJ, Lee YH.
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [Abstract] [Full Text] [Related]

  • 11. Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Lee YH, Song GG.
    Clin Drug Investig; 2020 Jan; 40(1):65-72. PubMed ID: 31602572
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC, Lee YH.
    Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC, Lee YH.
    Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
    [Abstract] [Full Text] [Related]

  • 14. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
    Sung YK, Lee YH.
    Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
    [Abstract] [Full Text] [Related]

  • 15. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P.
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis : Meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Z Rheumatol; 2017 Aug; 76(6):528-534. PubMed ID: 27312466
    [Abstract] [Full Text] [Related]

  • 17. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y, Gyu Song G.
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis.
    Lee YH, Song GG.
    Z Rheumatol; 2023 Feb; 82(1):64-70. PubMed ID: 33999266
    [Abstract] [Full Text] [Related]

  • 19. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
    Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P.
    Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
    Lee YH, Song GG.
    Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.